ArticleRare tumors2016
National Incidence, Management and Survival of Urachal Carcinoma.
Article in Rare tumors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis From 2006 to 2022.Annals of surgical oncology · 2026Article
- Robot‑assisted laparoscopic partial cystectomy for urachal carcinoma: A case report.Oncology letters · 2025Article
- Comprehensive analysis of targetable mutations and tumor microenvironment in urachal cancer.NPJ precision oncology · 2025Article
- Urachal adenocarcinoma in an adolescent boy: a case report.BMC pediatrics · 2024Article
- A remnant never forgotten: the utility of circulating tumor DNA in treatment guidance of urachal cancer.Therapeutic advances in medical oncology · 2024Article
- Article
- Two Patients with Urachal Cancer with Multifocal Adenocarcinoma Recurrences in the Urothelium of the Prostatic and Penile Urethra.European urology open science · 2021Article
- Primary urachal adenocarcinoma treated effectively with surgery and post operative chemoradiation therapy: Case Report with review of the literature.Radiology case reports · 2021Article
- Are urachal remnants really rare in children? An observational study.European journal of pediatrics · 2021Observational
- The Prognosis and Oncological Predictor of Urachal Carcinoma of the Bladder: A Large Scale Multicenter Cohort Study Analyzed 203 Patients With Long Term Follow-Up.Frontiers in oncology · 2021Article
- Current Understanding of Urachal Adenocarcinoma and Management Strategy.Current oncology reports · 2020Review
- Radical cystoprostatectomy to treat urachal carcinoma.Proceedings (Baylor University. Medical Center) · 2019Article
- Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.Virchows Archiv : an international journal of pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.